GSK wins $196m US BARDA contract for anthrax antitoxin raxibacumab
This article was originally published in Scrip
The US government has ordered 60,000 doses of GlaxoSmithKline's anthrax antitoxin raxibacumab under a four-year contract worth $196m with the Biomedical Advanced Research and Development Authority (BARDA).
You may also be interested in...
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.